Amy Nwankwo
Family Medicine · Gaithersburg, MDNPI 1467981167
Payments from drug & device makers
Across 51 payments — averaging $35.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$244
- Gilead$233
- AbbVie$191
- Sobi, Inc$133
- Merck$128
- Cranial Technologies, Inc$108
- plus $796 from 16 others
What the payments were for
- Food & beverage$1,76596%
- Education$674%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $244 |
| Gilead | 7 | $233 |
| AbbVie | 2 | $191 |
| Sobi, Inc | 3 | $133 |
| Merck | 6 | $128 |
| Cranial Technologies, Inc | 8 | $108 |
| Pfizer | 3 | $102 |
| Abbott | 1 | $90 |
| Corcept Therapeutics | 2 | $84 |
| Amgen | 1 | $79 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $75 |
| Cumberland Pharmaceuticals, Inc. | 2 | $54 |
| Genentech USA, Inc. | 1 | $52 |
| Johnson & Johnson | 1 | $49 |
| Exact Sciences | 2 | $46 |
| Novartis | 2 | $35 |
| Novo Nordisk | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $21 |
| Bayer | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,832 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 16 | $17,978 |
| MounjaroTirzepatide | 13 | $14,128 |
| JardianceEmpagliflozin | 11 | $13,815 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $13,289 |
| Lansoprazole | 12 | $3,581 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,628 |
| Quetiapine Fumarate | 24 | $833 |
| Gabapentin | 18 | $759 |
| Atorvastatin Calcium | 116 | $709 |
| Valproic AcidValproic Acid (As Sodium Salt) | 12 | $680 |
| Metformin Hcl | 81 | $568 |
| Famotidine | 22 | $519 |
| Diclofenac Sodium | 22 | $508 |
| Amlodipine Besylate | 82 | $461 |
| Levothyroxine Sodium | 36 | $402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $35 | $17,97816 claims |
| Lilly USA, LLCMounjaro | $12 | $14,12813 claims |
| Boehringer IngelheimJardiance | $21 | $13,81511 claims |
| MerckJanumet | $128 | $13,28912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Gaithersburg
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
- Sharon ChungGlen Burnie$333K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.